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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To examine the effects of occupational therapy delivered by occupational therapists compared to occupational therapy delivered by any
other person for people with schizophrenia. Our secondary objectives are to determine whether the response differs by specific type
(e.g. hospital versus non-hosptial setting), intensity (e.g. more therapist contact time or more frequent task repetition), or duration of
occupational therapy.
B A C K G R O U N D
Description of the condition
Schizophrenia is a severe mental illness that is characterised by
positive symptoms, such as hallucinations and delusions; negative
symptoms, such as catatonia, flattened affect, thought disorder
(disrupted speech), and lack of motivation; and cognitive symp-
toms, such as problems with memory and attention (Carpenter
1994; Fioravanti 2005; NIMH 2014). Schizophrenia can occur
as an isolated episode. However, for most people with schizophre-
nia it is a chronic illness characterised by a cycle of remission and
relapse, which often leads to long-term disability (Bustillo 2000).
It is among the top 15 medical conditions associated with im-
paired functioning (Murray 2013; NICE 2014). The first episode
of schizophrenia most frequently occurs in males in their early 20s
and females in their late 20s. It is associated with impairment of
both psychosocial and occupational functioning (APA 2013).
The World Health Organization (WHO) estimates that more
than 21 million people worldwide are living with schizophrenia
(WHO 2015). The median incidence of schizophrenia is esti-
mated at 15.2 cases per 100,000 of the general population with
lifetime prevalence estimated at 7.2 per 1000 of the general pop-
ulation (McGrath 2008). Prevalence is higher in males compared
to females (rate ratio 1.4:1) and the mortality risk for people with
schizophrenia is two to three times that of the general population,
with an all-cause standardised mortality ratio of 2.6:1 (McGrath
2008).
A number of factors, including migrant status, urban living, and
residence in developed countries, are also associated with an in-
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creased risk of schizophrenia (McGrath 2008; McGrath 2009).
The global burden of disease is substantial. Schizophrenia is de-
fined as the most disabling condition in this disease classification
group, and accounts for 7.4% of total disability-adjusted life years
(DALYs) attributable to mental and substance use disorders. The
peak burden occurs between 25 to 50 years of age (Whiteford
2013). It is estimated that only 21% of people of working age
with schizophrenia are in paid employment (Marwaha 2007), with
combined direct costs of treatment and indirect costs to society
(e.g. unemployment, absenteeism, and premature mortality) in
Englandduring2004/2005of aroundGBP6.7billion (Mangalore
2007). The cost of schizophrenia is estimated at GBP 11.8 billion
per year in England, with a public sector cost of GBP 7.2 billion
(Andrews 2012). The costs arise from a range of factors, including
inpatient time, loss of employment, disrupted education, home-
lessness, associated physical health problems, substance misuse,
contact with the criminal justice system, and unpaid care provided
by family members.
Description of the intervention
Occupational therapy is a complex intervention that incorporates
the dynamic interchange of a range of personal and environmen-
tal factors (Creek 2005). While antipsychotic drugs are the main-
stay of treatment for people with schizophrenia, these are often
only part of a larger package of care that involves multiple health-
care professionals and therapies. Occupational therapists are a core
member of multi-professional teams that care for people with
schizophrenia, and have unique skills in activity and occupational
analysis that complement the skills of other members of the multi-
professional team (Creek 2005; WFOT 2010).
Occupational therapy is designed to support and enable continued
participation in daily life through engagement in activities and oc-
cupations meaningful to the individual (WFOT 2010). Occupa-
tional therapists are uniquely trained to work across a broad range
of physical, mental health, and social settings where the emphasis
of therapy is on improving function rather than treating the symp-
toms of schizophrenia. Through modification of daily activities or
the environment, or both, occupational therapists facilitate mean-
ingful engagement in life activities (Creek 2003; WFOT 2010).
Occupational therapy is not prescriptive and a wide range of inter-
ventions are used when working with people, depending on their
individual needs, preferences, and interests (Creek 2005; WFOT
2010).Commonoccupational therapy interventions include help-
ing children with disabilities to participate fully in school and so-
cial situations, helping people recovering from injury to regain
skills, and providing support for older adults who are experiencing
physical and cognitive changes.
Schizophrenia impacts on a person’s ability to participate in ac-
tivities and engage with social roles (NICE 2014). Occupational
therapists work in both hospital and community settings using a
combination of individual and group interventions (Cook 2007;
Smith 2014). The occupational therapist aims to use the activities
that are important to the individual to help them increase skills
that can help them live a fulfilling life (Urlic 2010).
How the intervention might work
People with schizophrenia can experience difficulty engaging in
everyday life (Nagle 2002). This has been attributed to negative
symptoms (Mairs 2004), and to symptom severity (Bejerholm
2004).
Occupational therapy interventions for people with long-term
mental health issues, such as schizophrenia, aim to improve qual-
ity of life and social participation (Bryant 2014). This is achieved
through adaptation of activities and environments important to
the individual to enable skill development and building of their
confidence in the execution of everyday tasks (Bryant 2014; Cook
2007; Smith 2014). This may include:
• practical self care;
• domestic skills, such as cooking and budgeting;
• work skills;
• leisure activities;
• development of social skills;
• carer support.
Occupational therapy focuses on occupations and personal
strengths, rather than problems, and thereby promotes the devel-
opment of self-determination, confidence, and understanding of
health and well-being needs (COT 2006). Occupational thera-
pists are trained to analyse, grade, and adapt occupations to suit
personal circumstances and individual needs, and they actively in-
volve people with the therapy within the framework of their own
treatment and recovery journey. Occupational therapist-led inter-
ventions improve the quality of life and well-being for people with
long-termmental health conditions, such as schizophrenia (Aubin
1999). The development and maintenance of these skills has been
shown to reduce readmission to hospital (Smith 2014).
Why it is important to do this review
Currently there are nopublished formal evaluations of the evidence
on the effectiveness of specialist-administered occupational ther-
apy compared to occupational therapy delivered by other health-
care providers for people with schizophrenia. We aim to evaluate
the effectiveness of training specialised occupational therapists for
enhancing the outcomes of occupational therapy. This will pro-
vide clinically useful information to enhance the quality of care
among people with schizophrenia, to help clinicians in develop-
ing integrated care pathways and to assist health policymakers in
planning resource allocation.
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O B J E C T I V E S
To examine the effects of occupational therapy delivered by occu-
pational therapists compared to occupational therapy delivered by
any other person for people with schizophrenia. Our secondary
objectives are to determine whether the response differs by spe-
cific type (e.g. hospital versus non-hosptial setting), intensity (e.g.
more therapist contact time or more frequent task repetition), or
duration of occupational therapy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include all relevant randomised controlled trials (RCTs). If
a trial is described as ’double blind’ but implies randomisation, we
will include such trials in a sensitivity analysis (see the ’Sensitivity
analysis’ section). We will exclude quasi-randomised studies, such
as those that allocate participants by alternate days of the week.
Where people are given additional treatments alongside occupa-
tional therapy, we will only include data if the adjunct treatment
is evenly distributed between groups and only the occupational
therapy is randomised.
Types of participants
We will include people diagnosed with schizophrenia or related
disorders, including schizophreniform disorder, schizoaffective
disorder, and delusional disorder, by any means of diagnosis and
irrespective of age, sex or severity of illness. If trials include par-
ticipants with a range of mental illness, we will only include data
reported separately for people with schizophrenia.
We will aim to ensure that all information is as relevant to the cur-
rent care of people with schizophrenia as possible. Therefore, we
propose to clearly highlight the current clinical state (acute, early
post-acute, partial remission, remission), the stage (prodromal,
first episode, early illness, persistent) and whether the included
studies primarily focused on people with particular problems (e.g.
negative symptoms, treatment-resistant illnesses).
Types of interventions
1. Occupational therapy delivered by occupational therapists
The study publication is unlikely to report the credentials of occu-
pational therapists. We will therefore define an occupational ther-
apist as anyone the study authors describe as such.
2. Occupational therapy delivered by anyone other than
occupational therapists
For example, doctors, nurses, allied health professionals, or support
staff.
Where the included studies do not state who delivered the occupa-
tional therapy interventions, we will contact the study authors for
clarification. We will exclude studies where we were are unable to
ascertain which professionals delivered the occupational therapy.
Types of outcome measures
We aim to divide outcomes into short-term (less than six months),
medium-term (seven to 12 months), and long-term (more than
one year) outcomes.
Primary outcomes
1. Activities of daily living (ADL)
For example, standard occupational therapy assessments, such as
those based on the Model of Human Occupation (Kielhofner
2008) (such as the Model of Human Occupation Screeing Tool
(Parkinson 2006)), or Assessment of Motor and Process Skills
(AMPS 2010), or the Canadian Occupational Performance Mea-
sure (Law 2005).
1.1 Clinically important change ADL (as defined by individual
study)
2. Global state
2.1 Clinically important change global state (as defined by indi-
vidual study)
3. Adverse effect
3.1 Any clinically important adverse effect (as defined by individ-
ual study)
Secondary outcomes
1. Activities of daily living (ADL)
1.1 Any change in ADL (as defined by individual study)
1.2 Average endpoint/change score ADL scale
2. Global state
2.2 Any change in global state (as defined by individual study)
2.3 Average endpoint/change score global state scale e.g. the Brief
Psychiatric Rating Scale (BPRS) (Overall 1988)
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3. Adverse effect/event
3.1 Any specific effects (as defined by individual study)
3.2 Average endpoint/change score adverse effect scale
3.2 Death (suicide or natural cause)
4. Quality of life
4.1 Clinically important change quality of life (as defined by in-
dividual study)
4.2 Any change in quality of life (as defined by individual study)
4.3 Average endpoint/change score quality of life scale e.g. the
EuroQoL EQ-5D score (EuroQol Group 1990)
5. Social functioning
5.1 Clinically important change social functioning (as defined by
individual study)
5.2 Any change in social functioning (as defined by individual
study)
5.3 Average endpoint/change score social functioning scale e.g.
the Social Functioning Scale (Birchwood 1990), or the Social Oc-
cupational Functioning Scale (Saraswat 2006)
6. Employment status
Employment may be paid or unpaid, as defined by the original
included studies.
6.1 Number of participants in employment
7. Mental state
7.1 Clinically important change mental state (as defined by indi-
vidual study)
7.2 Any change in mental state
7.3 Average endpoint/change score mental state scale e.g. Scale for
the Assessment of Negative Symptoms (Andreasen 1989)
8. Service use
8.1 Hospital admission
8.2 Length of stay
9. Economic
9.1 Direct cost of care
9.2 Indirect cost of care
’Summary of findings’ table
We will use the GRADE approach to interpret findings (
Schünemann 2008). We will use GRADE to import data from
Review Manager (RevMan) 5.3 to create ’Summary of findings’
tables. These tables provide outcome-specific information con-
cerning the overall quality of evidence from each included study in
the comparison, the magnitude of the effect of the interventions
examined, and the sum of available data on all outcomes we rate as
important to patient care and decision making. We aim to include
the following main outcomes in the ’Summary of findings’ table:
• Activities of daily living: clinically important change (as
defined by individual study)
• Global state: clinically important change global state (as
defined by individual study)
• Social functioning: clinically important change social
functioning (as defined by individual study)
• Adverse effect: any significant adverse effect
• Quality of life: clinically important change quality of life (as
defined by individual study
• Employment status: number of participants in employment
• Service use: hospital admission
Search methods for identification of studies
Electronic searches
Cochrane Schizophrenia Group’s Trials Register
The Information Specalist of the Cochrane Schizophrenia Group
will search the Cochrane Schizophrenia Group’s Study-Based Reg-
ister of Trials using the following search strategy which has been
developed based on a literature review and in consultation with
the review authors:
(*(CMOP)* OR *(COPM)*OR *(MOHO)*OR * CMOP *OR
* COPM * OR *Domestic Skill* OR *Ergotherap* OR *KAWA
Model* OR *Meaningful Activit* OR * MOHO * OR *MO-
HOST* OR *Occupation* OR *Purposeful Activit* OR *Voca-
tion* OR *Volition* Questionnaire* OR *VQ*OR *Work Skill*)
in Title OR Abstract Fields of REFERENCE OR (*Ergotherapy*
OR *Occupation* OR *Vocation* OR (*Work* AND *Skill*)) in
Interventions Field of STUDY
In such a study-based register, searching the major concept re-
trieves all the synonym keywords and relevant studies because all
the studies are already organised based on their interventions and
linked to the relevant topics.
The Cochrane Schizophrenia Group’s Register of Trials is com-
piled by systematic searches of major resources (including AMED,
BIOSIS, CINAHL, Embase, MEDLINE, PsycINFO, PubMed,
and registries of clinical trials) and their monthly updates, hand-
searches, grey literature, and conference proceedings (see Group’s
Module). There are no language, date, document type, or publi-
cation status limitations for inclusion of records into the register.
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Searching other resources
1. Reference searching
We will inspect references of all included studies for further rele-
vant studies.
2. Personal contact
We will contact the first author of each included study for infor-
mation regarding unpublished trials. We will note the outcome of
this contact in the included or awaiting assessment studies tables.
Data collection and analysis
Selection of studies
Two review authors, KM and AS, will independently screen ci-
tations from the searches by title/abstract to identify articles that
potentially meet the inclusion criteria of the review. One review
author, SS, will independently re-inspect a random 20% sample
to ensure reliability of the review authors’ assessments. Where dis-
putes arise, we will retrieve the full-text article(s) for further as-
sessment. Two review authors, KM and AS, will obtain and in-
spect the full-text articles of potentially relevant abstracts. Again,
SS will re-inspect a random 20% of the reports in order to ensure
reliable selection. Where it is not possible to resolve disagreement
by discussion, we will attempt to contact the study authors for
clarification. We will list all excluded studies and their reasons for
exclusion in a ’Characteristics of excluded studies’ table. Also, we
were construct a PRISMA diagram to illustrate the study selection
process.
Data extraction and management
1. Extraction
Two review authors, KM and AS, will extract data from all in-
cluded studies. In addition, to ensure reliability, SS will indepen-
dently extract data from a random sample of these studies, which
will comprise 10% of the total. Again, we will discuss any dis-
agreement, document decisions, and, if necessary, contact study
authors for clarification. Review author SS will help to resolve any
remaining issues and we will document these final decisions in
the review text. We will attempt to extract data only presented in
graphs and figures whenever possible, but will include data only
if two review authors independently have the same result. We will
attempt to contact study authors through an open-ended request
in order to obtain missing information or for clarification when-
ever necessary. For multi-centre studies, where possible, we will
extract data relevant to each component centre separately.
2. Management
2.1 Forms
We will extract data onto standardised data extraction forms.
2.2 Scale-derived data
We will include continuous data from rating scales only if:
• the psychometric properties of the measuring instrument
have been described in a peer-reviewed journal (Marshall 2000);
and
• the measuring instrument has not been written or modified
by one of the trial authors for that particular trial.
Ideally the measuring instrument should either be:
• a self-report; or
• completed by an independent rater or relative (not the
therapist).
We realise that this is not often reported clearly, therefore we will
note the instrument mode of completion in the ’Description of
studies’ section of the review.
2.3 Endpoint versus change data
There are advantages of using both endpoint and change data.
Change data can remove a component of between-person variabil-
ity from the analysis. On the other hand, calculation of change
needs two assessments (baseline and endpoint), which can be dif-
ficult in unstable and difficult to measure conditions, such as
schizophrenia. We have decided to primarily use endpoint data,
and only use change data if the former are unavailable. We will
combine endpoint and change data in the analysis as we aim to
use mean difference (MD) values rather than standardised mean
difference (SMD) values throughout (Higgins 2011).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we will apply the following standards
to all data before inclusion.
For endpoint data N > 200
Wewill enter data from trials with at least 200 participants because
skewed data pose less of a problem in large studies.
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Change data
Wewill enter all change data because where continuous data scales
include potential negative values (such as change data), it is diffi-
cult to identify whether the data are skewed.
For endpoint data N < 200
• When a scale starts from the nite number zero, we will
subtract the lowest possible value from the mean, and divide this
by the standard deviation (SD). If this value is lower than one, it
strongly suggests a skew and we will exclude such data. If this
ratio is higher than one but below two, there is suggestion of
skew. We will enter these data and test whether their inclusion or
exclusion would change the results substantially. Finally, if the
ratio is larger than two we will include such data, because skew is
less likely (Altman 1996; Higgins 2011);
• if a scale starts from a positive value (such as the Positive
and Negative Syndrome Scale (PANSS) (Kay 1986), which can
have values from 30 to 210), we will modify the calculation
described above to take the scale starting point into account. In
these cases skew is present if 2 SD > (S-S min), where S is the
mean score and ’S min’ is the minimum score.
2.5 Common measure
To facilitate comparison between trials, we aim to convert variables
that can be reported in different metrics, such as days in hospital
(mean days per year, per week or per month) to a common metric
(e.g. mean days per month).
2.6 Conversion of continuous to binary
Where possible, we will attempt to convert outcome measures to
dichotomous data. This can be done by identifying cut-off points
on rating scales and dividing participants accordingly into ’clini-
cally improved’ or ’not clinically improved’. It is generally assumed
that if there is a 50% reduction in a scale-derived score, such as
the BPRS (Overall 1962) or the PANSS (Kay 1986), this could
be considered as a clinically significant response (Leucht 2005a;
Leucht 2005b). If data based on these thresholds are unavailable,
we will use the primary cut-off presented by the original study
authors.
2.7 Direction of graphs
Where possible, we will enter data in such a way that the area to
the left of the line of no effect indicates a favourable outcome for
occupational therapists.Where keeping to thismakes it impossible
to avoid outcome titles with clumsy double-negatives (e.g. ’not un-
improved’), we will report data where the left of the line indicates
an unfavourable outcome and note this in the relevant graphs.
Assessment of risk of bias in included studies
Two review authors, SS and KM, will independently assess the
risk of bias in the included trials using the criteria described in
the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011). This set of criteria is based on the evidence of
associations between the overestimate of effect and high risk of bias
of the article, such as sequence generation, allocation concealment,
blinding, incomplete outcome data, and selective reporting.
If the review authors disagree, we will decide the final rating by
consensus with the involvement of a third review author (AS).
Where included trials provide inadequate details of randomisation
and other characteristics of trials, we will contact the trial authors
in order to obtain further information. We will report non-con-
currence in quality assessment, and we will resolve by discussion
any disputes regarding to which category we will allocate a trial.
We will report the results of the ’Risk of bias’ assessments in the
included trials within the review text and in the ’Summary of
findings’ table.
Measures of treatment effect
1. Binary data
For binary outcomes we will calculate a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI). It has been
shown that RRs are more intuitive than odds ratios (ORs) (Boissel
1999), and clinicians tend to interpret ORs as RRs (Deeks 2000).
The number needed to treat for an additional beneficial outcome
(NNTH)/number needed to treat for an additional harmful out-
come (NNTH) statistic with its CIs is intuitively attractive to
clinicians, but is problematic both in its accurate calculation in
meta-analyses and interpretation (Hutton 2009). For binary data
presented in the ’Summary of findings’ table(s), we will calculate
illustrative comparative risks where possible.
2. Continuous data
For continuous outcomes we will estimate the MD between
groups. We prefer not to calculate effect size measures (SMD).
However, if the included trials use scales of very considerable sim-
ilarity, we will assume there is a small difference in measurement,
and we will calculate effect size and transform the effect back to
the units of one or more of the specific instruments.
Unit of analysis issues
1. Cluster-randomised trials
Studies increasingly employ cluster randomisation (such as ran-
domisation by clinician or practice), but analysis and pooling of
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clustered data poses problems. Firstly, study authors often fail to
account for intra-class correlation in cluster-randomised studies,
which leads to a ’unit of analysis’ error whereby P values are spu-
riously low, CIs unduly narrow, and statistical significance over-
estimated (Divine 1992). This causes type I errors (Bland 1997;
Gulliford 1999).
Where trial authors do not account for clustering in primary stud-
ies, we will present data in a table with an asterisk (*) to indicate
the presence of a probable unit of analysis error. In subsequent ver-
sions of this review we will seek to contact first authors of the in-
cluded studies to obtain intra-class correlation coefficients (ICCs)
for their clustered data and to adjust for this by using accepted
methods (Gulliford 1999). Where clustering has been incorpo-
rated into the analysis of primary studies, we will present these
data as if from a non-cluster randomised study but we will adjust
for the clustering effect.
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’de-
sign effect’. This is calculated using the mean number of partici-
pants per cluster (m) and theICC [Design effect = 1+(m-1)*ICC]
(Donner 2002). If the ICC is not reported we will assume it to be
0.1 (Ukoumunne 1999).
If cluster-randomised studies have been appropriately analysed
taking into account ICCs and relevant data documented in the re-
port, synthesis with other studies will be possible using the generic
inverse variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It oc-
curs if an effect (e.g. pharmacological, physiological, or psycho-
logical) of the treatment in the first phase is carried over to the
second phase. As a consequence, on entry to the second phase the
participants can differ systematically from their initial state despite
a wash-out phase. For the same reason, cross-over trials are inap-
propriate if the condition of interest is unstable (Elbourne 2002).
Cross-over study designs would be inappropriate for this inter-
vention (occupational therapists) as it would not be possible to
conceal the interventions or to avoid carry-over effects. However,
if we identify cross-over studies that meet the inclusion criteria
of this review, we will only use data from the first phase of these
studies in our analyses.
3. Studies with multiple treatment groups
Where a study involves more than two treatment arms, we will
present the additional treatment arms in comparisons if relevant. If
data are binary, we will simply add and combine these data within
the two-by-two table. If data are continuous, we will combine
data following the formula in Section 7.7.3.8 (Combining groups)
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). If the additional treatment arms are irrelevant, we
will not use these data.
Dealing with missing data
1. Overall loss of credibility
Data must lose credibility at some degree of loss of follow-up
(Xia 2009). Should more than 50% of data be unaccounted for
regarding any particular outcome, we will not reproduce these
data or use them within analyses. If, however, more than 50%
of those in one study arm are lost, but the total loss is less than
50%,wewill address this within the ’Summary of findings’ table(s)
by downgrading the quality of the evidence. Finally, we will also
downgrade the quality of the evidence should the loss be between
25% to 50% in total.
2. Binary
In the case where attrition for a binary outcome is between 0% and
50% and where the trial authors do not clearly describe these data,
we will present data on an intention-to-treat (ITT) basis. We will
assume that those participants that leave the study early have the
same rates of negative outcome as those who complete the study,
with the exception of the outcomes of death and adverse effects.
For these outcomes, we will use the rate of those who stay in the
study - in that particular trial arm - for those who did not. We
will undertake a sensitivity analysis to test how prone the primary
outcomes are to change when we compare data only from people




In the case where attrition for a continuous outcome is between
0% and 50%, and the trial(s) only report data from people who
complete the study to that point, we will use these data.
3.2 SDs
If the included trials do not report SD values, we will first try
to obtain the missing values from the trial authors. If these data
are unavailable, where there are missing measures of variance for
continuous data, but an exact standard error (SE) and CIs are
available for group means, and either the P value or ’t’ value are
available for the MDs, we will calculate them according to the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). When the trial authors only report the SE values, we will
calculate SD values using the formula SD = SE * square root (n).
Chapters 7.7.3 and 16.1.3 of theCochrane Handbook for Systematic
Reviews of Interventions present detailed formula for estimating
SDs from P values, t or F values, CIs, ranges, or other statistics
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(Higgins 2011). If these formula do not apply, we will calculate
the SDs according to a validated imputation method which is
based on the SDs of the other included studies (Furukawa 2006).
Although some of these imputation strategies can introduce error,
the alternative would be to exclude a given study’s outcome and
thus to lose information. Neverthelesswe will examine the validity
of the imputations in a sensitivity analysis by excluding imputed
values.
3.3 Assumptions about participants who left the trials early
or were lost to follow-up
Variousmethods are available to account for participants who leave
the trials early or are lost to follow-up. Some trials just present the
results of study completers, while other studies use the method of
last observation carried forward (LOCF). More recently, methods
such as multiple imputation or mixed-effects models for repeated
measurements (MMRM) have become more of a standard. While
the latter methods seem to be somewhat better than LOCF (Leon
2006), we feel that the high percentage of participants leaving the
studies early and the differences in the reasons for leaving the stud-
ies early between groups is often the core problem in randomised
trials of people with schizophrenia. Therefore, we will not exclude
studies based on the statistical approach the trial authors use.How-
ever, we will preferably use themore sophisticated approaches, e.g.
we will prefer MMRM or multiple-imputation to LOCF and we
will only present completer analyses if some kind of ITT data are
unavailable at all. Moreover, we will address this issue in the ’in-
complete outcome data’ item of the ’Risk of bias’ tool.
Assessment of heterogeneity
1. Clinical heterogeneity
Wewill consider all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We will simply in-
spect all studies for clearly outlying participants or situations that
we had not predicted would arise. When such situations or par-
ticipant groups arise, we will fully discuss.
2. Methodological heterogeneity
Wewill consider all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity.We will sim-
ply inspect all studies for clearly outlying methods that we had not
predicted would arise. When such methodological outliers arise,
we will fully discuss.
3. Statistical heterogeneity
3.1 Visual inspection
We will visually inspect graphs to investigate the possibility of
statistical heterogeneity.
3.2 Employing the I2 statistic
We will investigate heterogeneity between studies by considering
the I2 statistic method alongside the Chi2 test P value. The I2
statistic provides an estimate of the percentage of inconsistency
thought to be due to chance (Higgins 2003). The importance of
the observed value of I2 statistic depends on:
• the magnitude and the direction of effects; and
• the strength of the evidence for heterogeneity (e.g. P value
from Chi2 test, or a CI for the I2 statistic value).
We will interpret an I2 statistic estimate greater than or equal to
around 50% accompanied by a statistically significant Chi2 test
value as evidence of substantial levels of heterogeneity (Section
9.5.2 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011)). When we observe substantial levels of
heterogeneity in the primary outcome, we will explore the reasons
for heterogeneity (see the ’Subgroup analysis and investigation of
heterogeneity’ section).
Assessment of reporting biases
1. Protocol versus full study
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results. These are de-
scribed in Section 10.1 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We will try to locate pro-
tocols of included randomised trials. If the protocol is available,
we will compare outcomes in the protocol and in the published
report. If the protocol is not available, we will compare outcomes
listed in the methods section of the trial report with actually re-
ported results.
2. Funnel plot
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are again described in Section 10 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).We are aware
that funnel plots may be useful in investigating reporting biases
but are of limited power to detect small-study effects. We will not
use funnel plots for outcomes where there are 10 or fewer included
studies, or where all studies are of similar size. In other cases, where
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funnel plots are possible, we will seek statistical advice in their
interpretation.
Data synthesis
We understand that there is no closed argument for preference
for use of fixed- or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model. It places added weight on small studies,
which are often the most biased ones. Depending on the direction
of effect, these studies can either inflate or deflate the effect size.
Occupational therapists deliver therapy that is diverse in nature
and we may therefore make an a priori assumption that included
studies will estimate different but related effects. We will therefore
use a random-effects model for all analyses.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
1.1 Primary outcomes
For the primary outcomes we will, if possible, determine whether
the response to therapy varies according to the following sub-
groups:
• duration of therapy: short- (up to eight weeks) versus long-
term;
• specific type: hospital versus non-hosptial setting;
• intensity: more therapist contact time or more frequent task
repetition (intensive programme).
1.2 Clinical state, stage, or problem
We propose to undertake this review and provide an overview
of the effects of occupational therapy delivered by occupational
therapists for people with schizophrenia in general. However, if
the included trials report data for subgroups of people in the same
clinical state, stage, and with similar problems, we will report these
for the primary outcomes.
2. Investigation of heterogeneity
Wewill report whether inconsistency is high. First, we will investi-
gate whether data are entered correctly. Second, if data are correct
we will visually inspect the graph and successively remove studies
outside of the company of the rest to see if homogenity is restored.
For this Cochrane Review we have decided that should this occur
with data contributing to the summary finding of no more than
around 10% of the total weighting, we will present such data. If
not, we will not pool data and will discuss any relevant issues. We
know of no supporting research for this 10% cut-off but we are
investigating use of prediction intervals as an alternative to this
unsatisfactory state.
When unanticipated clinical or methodological heterogeneity are
obvious, we will simply state hypotheses regarding these for future
reviews or future versions of this review. We do not anticipate
undertaking analyses relating to these.
Sensitivity analysis
1. Implication of randomisation
We aim to include trials in a sensitivity analysis if the trial authors
describe them in some way as to imply randomisation. For the
primary outcomes we will include these studies. If their inclusion
does not result in a substantive difference, they will remain in
the analyses. If their inclusion does result in important clinically
significant but not necessarily statistically significant differences,
we will not add the data from these lower quality studies to the
results of the better quality trials, but will present such data within
a subcategory.
2. Assumptions for lost binary data
Where we have to make assumptions regarding participants lost
to follow-up (see the ’Dealing with missing data’ section), we will
compare the findings of the primary outcomes when we use our
assumption(s) and when we use data only from participants who
complete the study to that point. If there is a substantial difference,
we will report the results and discuss them but will continue to
employ our assumption.
Where we must make assumptions regarding missing SD data
(see the ’Dealing with missing data’ section), we will compare the
findings of the primary outcomes when we use our assumption(s)
and when we use data only from participants who complete the
study to that point. We will undertake a sensitivity analysis to test
how prone the results are to change when we compare completer-
only data only to the imputed data using the above assumption.
If there is a substantial difference, we will report the results and
discuss them but will continue to employ our assumption.
3. Risk of bias
For the primary outcomes, we will analyse the effects of excluding
trials that we judge to be at high risk of bias across one or more
of the domains of randomisation (implied as randomised with
no further details available, allocation concealment, blinding, and
outcome reporting). If the exclusion of trials at high risk of bias
does not substantially alter the direction of effect or the precision
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of the effect estimates, then we will include the data from these
trials in the analysis.
4. Imputed values
For the primary outcomes, we will undertake a sensitivity analysis
to assess the effects of including data from trials where we use
imputed values for the ICC in calculating the design effect in
cluster-randomised trials.
If we note substantial differences in the direction or precision of
effect estimates in any of the sensitivity analyses we have listed
above, we will not pool data from the excluded trials with the other
trials that contribute to the outcome, but we will present them
separately.
5. Fixed- and random-effects models
Wewill synthesise all data using a random-effectsmodel.However,
we will also synthesise data for the primary outcome using a fixed-
effect model to evaluate whether this alters the significance of the
results.
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